The study aims to investigate, using real-world data, if the application of one-year adjuvant trastuzumab, in cases of early HER2-positive breast cancer, is beneficial to the health outcomes of women concerning the costs (cost-effectiveness analysis). The gene discussed is ERBB2; the disease is breast cancer.